Effects of pain, sedation and analgesia on neonatal brain injury and brain development.

Semin Perinatol

Pediatrics, BC Children's Hospital Research Institute and University of British Columbia, Vancouver, BC, Canada; Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada; Neurosciences and Mental Health, SickKids Research Institute, Toronto, ON, Canada. Electronic address:

Published: August 2024

Critically ill newborns experience numerous painful procedures as part of lifesaving care in the Neonatal Intensive Care Unit. However, painful exposures in the neonatal period have been associated with alterations in brain maturation and poorer neurodevelopmental outcomes in childhood. The most frequently used medications for pain and sedation in the NICU are opioids, benzodiazepines and sucrose; these have also been associated with abnormalities in brain maturation and neurodevelopment making it challenging to know what the best approach is to treat neonatal pain. This article provides clinicians with an overview of how neonatal exposure to pain as well as analgesic and sedative medications impact brain maturation and neurodevelopmental outcomes in critically ill infants. We also highlight areas in need of future research to develop standardized neonatal pain monitoring and management strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semperi.2024.151928DOI Listing

Publication Analysis

Top Keywords

brain maturation
12
pain sedation
8
critically ill
8
neurodevelopmental outcomes
8
neonatal pain
8
neonatal
6
brain
5
effects pain
4
sedation analgesia
4
analgesia neonatal
4

Similar Publications

Cannabis derivatives are among the most widely used psychoactive substances in the world, which leads to growing medical concerns regarding its chronic use and abuse especially among adolescents. Exposure to THC during formative years produces long-term behavioral alterations that share similarities with symptoms of psychiatric and neurodevelopmental disorders. In this study, we have analyzed the functional and molecular mechanisms that might underlie these alterations.

View Article and Find Full Text PDF

Background: Imaging and plasma markers are used as key indicators of disease for Alzheimer's disease (AD) but their usefulness in predicting regional tau pathology is relatively understudied. Our objective was to construct predictive models for regional tau pathology measured on postmortem brain tissue using multiple ante-mortem AD biomarkers. We focused on hippocampal and parietal regions that were immunostained with AT8 and 2E9 that reflect early and advanced aspects of tangle maturity, respectively.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Washington University in St. Louis, Saint Louis, MO, USA.

Background: Alzheimer disease (AD) is a chronic progressive neurodegenerative disorder that presents with cognitive dysfunction, memory loss, language difficulties, emotion dysregulation, and the eventual loss of motor function and death. Magnetic resonance imaging (MRI) shows early atrophy in the medial temporal lobes, which then spreads to the posterior temporal lobe, parietal lobe, and finally the frontal lobe with relative sparing of the sensorimotor cortex. Social disadvantage has been shown to have potentially additive impacts on aging trajectories.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland.

Background: Alzheimer's disease (AD) is an uncurable, heterogeneous, and molecular complex neurodegenerative disease. Emerging evidence indicates that furin could play an essential role in the pathogenesis of neurodegenerative disorders. Furin participates in the proteolytic maturation and processing of large numbers of prohormones and proproteins, which among others play crucial roles in neuronal survival, axon growth, dendritic development, synaptogenesis, neurodegeneration, and inflammation.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD), the most common type of dementia, affects at least twenty-four million people globally, yet, the causation, mechanisms of progression, and therapeutic strategies remain elusive. Currently, tRNA-derived RNA fragments (tRFs), a family of recently discovered small non-coding RNAs (sncRNAs), have surfaced as promising biomarkers for many diseases, including AD. Our work revealed that several AD-impacted tRFs in human hippocampus, CSF, and serum.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!